Converge Bio Secures $25M From Bessemer, Meta, OpenAI, Wiz Execs
▼ Summary
– AI is being rapidly adopted in drug discovery to accelerate R&D and improve success rates, with over 200 startups now competing in this space.
– Converge Bio, a startup using generative AI trained on molecular data, raised a $25 million Series A round to help pharmaceutical companies speed up drug development.
– The company offers integrated, ready-to-use AI systems for tasks like antibody design and protein optimization, which plug directly into client workflows.
– Converge has grown quickly, securing 40 partnerships and running about 40 programs, while expanding its team and publishing successful case studies.
– The field is shifting from trial-and-error to data-driven design, though challenges like AI hallucinations remain, which Converge addresses by pairing generative models with predictive filters.
The race to accelerate drug development is intensifying, with over two hundred startups now vying to integrate artificial intelligence into pharmaceutical research. Converge Bio, a startup operating from Boston and Tel Aviv, has successfully secured a significant $25 million in Series A funding to advance its position in this competitive field. The investment round was led by Bessemer Venture Partners, with participation from TLV Partners and Vintage Investment Partners. Notably, the funding also included backing from senior executives at major tech firms Meta, OpenAI, and Wiz, signaling strong cross-industry interest in AI’s potential to reshape medicine.
Converge Bio specializes in applying generative AI models trained on molecular data, including DNA, RNA, and protein sequences, to streamline and accelerate the drug development process for its pharmaceutical and biotech partners. According to CEO and co-founder Dov Gertz, the company’s platform is designed to support experiments across the entire drug-development lifecycle, from initial target identification through to clinical trials and manufacturing. The goal is to help bring new therapeutics to market more rapidly.
The startup has already launched three distinct AI systems for its customers. These include platforms for antibody design, protein yield optimization, and biomarker and target discovery. Gertz emphasizes that the true value lies in providing complete, integrated systems rather than individual models. For instance, the antibody design system combines a generative model to create novel antibodies, predictive models to filter them based on molecular properties, and a physics-based docking system to simulate 3D interactions with targets. This integrated approach means clients receive ready-to-use tools that plug directly into their existing research workflows without needing to assemble complex components themselves.
This new capital infusion arrives roughly eighteen months after the company’s $5.5 million seed round in 2024. In that short time, Converge has scaled operations considerably. The company now reports 40 active partnerships with biotech and pharma firms and is managing approximately 40 programs on its platform. Its client base spans North America, Europe, and Israel, with expansion into Asian markets now underway. The team has also grown dramatically, from nine employees in late 2024 to 34 today.
The startup has begun publishing public case studies to demonstrate its platform’s efficacy. In one example, Converge helped a partner increase protein yield by four to four-and-a-half times in just one computational iteration. In another, the platform generated antibodies exhibiting extremely high binding affinity, reaching the single-nanomolar range.
This progress occurs against a backdrop of surging momentum for AI in life sciences. Recent landmarks include Eli Lilly’s partnership with Nvidia to build a powerful supercomputer for drug discovery and the 2024 Nobel Prize in Chemistry awarded to the developers of Google DeepMind’s protein-structure-predicting AI, AlphaFold. Gertz observes that the industry is undergoing a fundamental shift from traditional trial-and-error methods toward data-driven molecular design, creating what he believes is the largest financial opportunity in the history of life sciences.
While large language models (LLMs) are attracting attention for their ability to analyze biological data, challenges like AI “hallucinations” pose particular risks in drug discovery. Validating a novel compound can take weeks, making inaccurate suggestions costly. Converge addresses this by pairing its generative models with predictive filters to reduce risk and improve outcomes for partners. Gertz also clarified the company’s stance on LLMs, noting that while they are useful as support tools, for instance, to help navigate scientific literature, they are not the core technology for understanding biology. For that, models must be trained directly on molecular data like DNA and proteins.
“Our vision is for every life-science organization to use Converge Bio as its generative AI lab,” Gertz stated. He envisions a future where traditional wet labs are complemented by computational generative labs that create hypotheses and molecules. “We want to be that generative lab for the entire industry.”
(Source: TechCrunch)
